Esmilkrys Ramirez, MD
Obesity Medicine · Chicago, ILNPI 1083880546
Payments from drug & device makers
Across 653 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novo Nordisk$2K
- AbbVie$2K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$1K
- Bioventus LLC$1K
- plus $4K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 124 | $3,110 |
| Novo Nordisk | 120 | $1,966 |
| AbbVie(2 entities) | 86 | $1,761 |
| Lilly USA, LLC | 72 | $1,431 |
| Boehringer Ingelheim | 50 | $1,167 |
| Bioventus LLC | 5 | $1,005 |
| Bayer | 29 | $890 |
| Amgen | 28 | $604 |
| Pfizer | 24 | $498 |
| Corcept Therapeutics | 6 | $373 |
| Merck | 20 | $317 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $306 |
| GSK | 8 | $168 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $167 |
| Sanofi-aventis U.S. LLC | 6 | $135 |
| Johnson & Johnson | 5 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $121 |
| Ardelyx, Inc. | 4 | $108 |
| Exact Sciences | 4 | $106 |
| Seqirus USA Inc | 4 | $83 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| VBI Vaccine (delaware) Inc. | 3 | $60 |
| Redhill Biopharma Inc. | 3 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Azurity Pharmaceuticals, Inc. | 2 | $34 |
| Radius Health, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $25 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
| Abbott | 1 | $20 |
| Gilead | 1 | $19 |
| Eli Lilly | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Avion Pharmaceuticals | 1 | $13 |
How this compares
Too few obesity medicine providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other obesity medicine in Chicago
- Mona LalaChicago$822
- Omar ShamsiElmhurst$39K
- Jeffrey PuaWestmont$25K
- Diana PlataArlington Heights$19K
- Diala AlatassiElmhurst$815
- Esther SchulzMount Vernon$485
- Catherine JohnsonClarendon Hills$324
- Darshan PatelDeer Park$266
- Lyndsay HoffmanArlington Heights$219
- Manali PatelBloomingdale$211
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.